Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants.
Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants.
复制标题
DOI：
10.1038/s41586-021-04117-7
复制
发表时间：
2021-12
期刊：
影响因子：
64.8
通讯作者：
Rappuoli R
中科院分区：
文献类型：
--
作者：
Andreano E;Paciello I;Piccini G;Manganaro N;Pileri P;Hyseni I;Leonardi M;Pantano E;Abbiento V;Benincasa L;Giglioli G;De Santi C;Fabbiani M;Rancan I;Tumbarello M;Montagnani F;Sala C;Montomoli E;Rappuoli R
SARS-CoV-2变体的出现正在危及现有疫苗的有效性，并限制了基于单克隆抗体的COVID-19治疗的应用（参考文献）。． 在这里，我们分析了5名接种了BNT162b2 mRNA疫苗的新生儿和5名康复期患者的记忆B细胞，以研究B细胞的性质和单细胞水平上的抗体反应。对近6000个细胞进行了分类，3000多个细胞产生了针对刺突蛋白的单克隆抗体，400多个细胞中和了最初在中国武汉发现的SARS-CoV-2病毒。B.1.351 （Beta）和B.1.1.248 （Gamma）变体几乎逃脱了这些抗体的70%，而B.1.1.7 （Alpha）和B.1.617.2 （Delta）变体的影响要小得多。来自幼稚人群的抗体中，中和的总体损失总是显著更高。部分原因是IGHV2-5；IGHJ4-1种系，仅在恢复期人群中发现，并产生强效和广泛中和的抗体。我们的数据表明，感染或初次接种疫苗后血清呈阳性的人将产生效力和广度更高的抗体，并能够更好地控制新出现的SARS-CoV-2变体。单细胞水平分析记忆B细胞及其对接种所有SARS-CoV-2变体疫苗的反应，这些人以前曾或未接触过该病毒。
The emergence of SARS-CoV-2 variants is jeopardizing the effectiveness of current vaccines and limiting the application of monoclonal antibody-based therapy for COVID-19 (refs. ). Here we analysed the memory B cells of five naive and five convalescent people vaccinated with the BNT162b2 mRNA vaccine to investigate the nature of the B cell and antibody response at the single-cell level. Almost 6,000 cells were sorted, over 3,000 cells produced monoclonal antibodies against the spike protein and more than 400 cells neutralized the original SARS-CoV-2 virus first identified in Wuhan, China. The B.1.351 (Beta) and B.1.1.248 (Gamma) variants escaped almost 70% of these antibodies, while a much smaller portion was impacted by the B.1.1.7 (Alpha) and B.1.617.2 (Delta) variants. The overall loss of neutralization was always significantly higher in the antibodies from naive people. In part, this was due to the IGHV2-5;IGHJ4-1 germline, which was found only in people who were convalescent and generated potent and broadly neutralizing antibodies. Our data suggest that people who are seropositive following infection or primary vaccination will produce antibodies with increased potency and breadth and will be able to better control emerging SARS-CoV-2 variants. Single-cell-level analysis of memory B cells and their response to vaccination against all SARS-CoV-2 variants of concern in individuals who either had or had not been previously exposed to the virus.
登录
查看更多内容
影响因子：
--
作者：
Kepler TB
通讯作者：
Kepler TB
DOI：
10.1126/science.abf9302
发表时间：
2021-02-19
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Starr TN;Greaney AJ;Addetia A;Hannon WW;Choudhary MC;Dingens AS;Li JZ;Bloom JD
通讯作者：
Bloom JD
影响因子：
64.5
作者：
Andreano E;Nicastri E;Paciello I;Pileri P;Manganaro N;Piccini G;Manenti A;Pantano E;Kabanova A;Troisi M;Vacca F;Cardamone D;De Santi C;Torres JL;Ozorowski G;Benincasa L;Jang H;Di Genova C;Depau L;Brunetti J;Agrati C;Capobianchi MR;Castilletti C;Emiliozzi A;Fabbiani M;Montagnani F;Bracci L;Sautto G;Ross TM;Montomoli E;Temperton N;Ward AB;Sala C;Ippolito G;Rappuoli R
通讯作者：
Rappuoli R
影响因子：
24.8
作者：
Goel RR;Apostolidis SA;Painter MM;Mathew D;Pattekar A;Kuthuru O;Gouma S;Hicks P;Meng W;Rosenfeld AM;Dysinger S;Lundgreen KA;Kuri-Cervantes L;Adamski S;Hicks A;Korte S;Oldridge DA;Baxter AE;Giles JR;Weirick ME;McAllister CM;Dougherty J;Long S;D'Andrea K;Hamilton JT;Betts MR;Luning Prak ET;Bates P;Hensley SE;Greenplate AR;Wherry EJ
通讯作者：
Wherry EJ
DOI：
10.1126/science.abg5268
发表时间：
2021-06-04
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Voss WN;Hou YJ;Johnson NV;Delidakis G;Kim JE;Javanmardi K;Horton AP;Bartzoka F;Paresi CJ;Tanno Y;Chou CW;Abbasi SA;Pickens W;George K;Boutz DR;Towers DM;McDaniel JR;Billick D;Goike J;Rowe L;Batra D;Pohl J;Lee J;Gangappa S;Sambhara S;Gadush M;Wang N;Person MD;Iverson BL;Gollihar JD;Dye JM;Herbert AS;Finkelstein IJ;Baric RS;McLellan JS;Georgiou G;Lavinder JJ;Ippolito GC
通讯作者：
Ippolito GC